An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumours That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists

Trial Profile

An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumours That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 07 May 2010 Actual end date ( Nov 2009) added as reported by ClinicalTrials.gov.
    • 07 May 2010 Actual end date ( Nov 2009) added as reported by ClinicalTrials.gov.
    • 17 Sep 2009 Results in basal cell carcinoma expansion cohort published in NEJM.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top